Answers are grounded in this paper and cite their sources.
Attention to characteristic MRI patterns, especially the presence of contrast enhancement, and the subcortical location may have utility in screening and early diagnosis of PML in natalizumab-treated MS patients.
No takes yet. Share an insight, caveat, or question.
Yousry et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: